Table 3 Comparison of patients with 90-day mRS 0–2 and mRS > 2

Sex

0.365

  Male

32

23 (67.6 %)

9 (52.9 %)

  Female

19

11 (32.4 %)

8 (47.1 %)

Age (years)

68.3

(61.4–76)

67.6

(55.6–74.5)

69

(63.1–77)

0.374

TICI

< 0.001

  0-2 A

9

0 (0 %)

9 (52.9 %)

  2B-3

42

34 (100 %)

8 (47.1 %)

Diabetes

0.345

  Yes

16

9 (26.5 %)

7 (41.2 %)

  No

35

25 (73.5 %)

10 (58.8 %)

Hyperlipidemia

0.569

  Yes

24

15 (44.1 %)

9 (52.9 %)

  No

27

19 (55.9 %)

8 (47.1 %)

Hypertension

0.745

  Yes

36

23 (67.7 %)

13 (76.5 %)

  No

15

11 (32.3 %)

4 (23.5 %)

Atrial fibrilation

0.673

  Yes

7

4 (11.8 %)

3 (17.6 %)

  No

44

30 (88.2 %)

14 (82.3 %)

ASPECTS

0.254

  9–10

27

20 (58.9 %)

7 (41.2 %)

  8 or less

24

14 (41.2 %)

10 (58.8 %)

Occlusion type

1

  Atherosclerotic

38

25 (73.5 %)

13 (76.5 %)

  Dissection

13

9 (26.5 %)

4 (23.5 %)

Occlusion location

0.241

  Tandem

42

26 (76.5 %)

16 (94.1 %)

  Extracranial

9

8 (23.5 %)

1 (5.9 %)

Preprocedural therapy

0.081

  Yes

21

17 (50.0 %)

4 (23.5 %)

  No

30

17 (50.0 %)

13 (76.5 %)

Intraprocedural therapy

0.757

  Yes

18

13 (38.2 %)

5 (26.5 %)

  No

33

21 (61.8 %)

12 (70.6 %)

Postprocedural therapy

0.008

  ASA

15

8 (23.5 %)

7 (41.2 %)

  ASA + Clopidogrel

33

26 (76.5 %)

7 (41.2 %)

  Heparin/none

3

0 (0 %)

3 (17.6 %)

Hemorrhagic transformation

0.001

  Yes

10

2 (5.9 %)

8 (47.1 %)

  No

41

32 (94.1 %)

9 (52.9 %)

  Procedure time (minutes)

69

(46–90)

60

(45–76.8)

86

(55–119)

0.031

Extracranial technique

0.597

  PTA

18

11 (32.3 %)

7 (41.2 %)

  Stent

6

4 (11.8 %)

2 (11.8 %)

  PTA + Stent

15

12 (35.3 %)

3 (17.6 %)

  None/other

12

7 (20.6 %)

5 (26.5 %)

Intracranial technique

0.098

  ADAPT

28

20 (58.8 %)

8 (47.1 %)

  Solumbra

11

4 (11.8 %)

7 (41.2 %)

  Retriever

2

2 (5.9 %)

0 (0 %)

  None

10

8 (23.5 %)

2 (11.8 %)

Stent

0.366

  Yes

21

16 (47.1 %)

5 (26.5 %)

  No

30

18 (52.9 %)

12 (70.6 %)